Schizophrenia Research
Volume 44, Issue 3 , Pages 165-175 , 1 September 2000

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

Received 28 December 1998 ,Accepted 3 September 1999.

References 

  1. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 1995;345:99–103
  2. Alonso R, Chaudieu I, Diorio J, Krishnamurthy A, Quirion R, Boksa B. Interleukin-2 modulates evoked release of [3H] dopamine in rat cultured mesencephalic cells. J. Neurochem. 1993;61:1284–1290
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn.. Washington, DC: American Psychiatric Press; 1994;
  4. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1983;
  5. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983;
  6. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 1996;20:199–203
  7. Bertini R, Garattini S, Delgado R, Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunol. 1993;79:217–219
  8. Boukhris W, Kouassi E, Revillard JP. Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacol. Immunotoxicol. 1988;10:501–512
  9. Caruso C, Candore G, Cigna D, Colucci AT, Modica MA. Biological significance of soluble IL-2 receptor. Med. Inflamm. 1993;2:3–21
  10. Crow TJ. Molecular pathology of schizophrenia: more than one disease process. Br. Med. J. 1980;280:66–68
  11. Davis KL, Kann RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 1991;148:1474–1486
  12. De Jongh R, Vranken J, Vundelinckx G, Bosmans E, Maes M, Heylen R. The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. Cytokine. 1997;9:696–701
  13. DeLisi LE, Goodman S, Neckers LM, Wyatt RJ. An analysis of lymphocyte subpopulations in schizophrenic patients. Biol. Psychiatry. 1982;17:1003–1009
  14. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 1987;107:293–300
  15. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiat. Clin. Neurosci. 1997;247:228–233
  16. Ganguli R, Rabin BS. Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. Arch. Gen. Psychiatry. 1989;46:292
  17. Ganguli R, Rabin BS, Kelly RH, Lyne M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. N.Y. Acad. Sci. 1987;496:676–685
  18. Ganguli R, Yang Z, Shurin G, Chengappa KNR, Brar JS, Gubbi AV, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994;51:1–10
  19. Ganguli R, Brar JS, Chengappa KNR, Deleo M, Yang ZW, Shurin G, et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch. Gen. Psychiatry. 1995;52:668–672
  20. Gattaz WF, Dalgalarrondo P, Schroder HC. Abnormalities in serum concentrations of interleukin-2, interferon-α and interferon-γ in schizophrenia not detected. Schizophr. Res. 1992;6:237–241
  21. Gaughran F, O'Neill E, Cole M, Collins K, Daly RJ, Shanahan F. Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophr. Res. 1998;29:263–267
  22. Hanisch UK, Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev. 1996;21:246–284
  23. Henneberg A, Riedl B, Dumke HO, Kornhuber HH. T lymphocyte subpopulations in schizophrenic patients. Eur. Arch. Psychiat. Neurol. Sci. 1990;239:283–284
  24. Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 1994;12:29–34
  25. Kim YK, Lee MS, Hahm W, Lee KH, Lee CK. Relationships between acute phase proteins and activities of interleukin-1β, interleukin-6 in schizophrenic patients. Seoul J. Psychiatry. 1994;19:179–186
  26. Kim YK, Lee MS, Suh KY. Decreased IL-2 production in Korean schizophrenic patients. Biol. Psychiatry. 1998;43:701–704
  27. Kirch DG. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 1993;19:355–370
  28. Lapchak PA. A role for IL-2 in the regulation of striatal dopaminergic function. Neuroreport. 1992;3:165–168
  29. Lapchak PA, Araujo DM, Quirion R, Beaudet A. Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neurosci. 1991;44:173–184
  30. Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacol. 1997;37:75–86
  31. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry. 1993;150:1408–1410
  32. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr. Bull. 1993;19:371–429
  33. Lin A, Kenis G, Bignotti S, Tura GJB, De Jongh R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998;32:9–15
  34. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 1994;89:346–351
  35. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995;29:141–152
  36. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 1996;21:39–50
  37. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. Acute phase proteins in schizophrenia, mania, and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66:1–11
  38. Maes M, Bosmans E, Kenis G, De Jongh R, Smith RS, Meltzer HY. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 1997;26:221–225
  39. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. Increases in CSF levels of IL-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry. 1995;152:1291–1297
  40. Muller N, Hofschuster E, Ackenheil M, Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiat. Scand. 1993;87:66–71
  41. Muller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiat. Clin. Neurosci. 1997;247:308–313
  42. Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 1996;20:269–273
  43. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia?. Schizophr. Res. 1997;26:227–233
  44. Petitto JM, McCarthy DB, Rinker CM, Huang Z, Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol. 1997;73:183–190
  45. Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. 1991;15:185–215
  46. Pollmacher T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am. J. Psychiatry. 1997;154:1763–1765
  47. Rapaport MH, McAllister CG, Nelson DL, Pickar D, Paul SM. Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch. Gen. Psychiatry. 1989;46:291–292
  48. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL, et al. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol. Psychiatry. 1994;35:767–771
  49. Riches P, Gooding R, Millar BC, Rowbottom AW. Influence of collection and separation of blood samples on plasma Il-1, Il-6 and TNF-α concentrations. J. Immunol. Meth. 1992;153:125–131
  50. Roth RH, Bacopoulos NG. Plasma dopamine metabolites: useful indices of central dopamine metabolism?. In:  Usdin E,  Kopin IJ,  Barchas J editor. Catechoamines: Basic and Clinical Frontiers. New York: Pergamon Press; 1979;p. 681–683
  51. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiol. 1998;37:186–193
  52. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 1995;56:2209–2222
  53. Seegal RF, Brosch KO, Bush B. High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and serum. J. Chromatogr. 1986;377:131–144
  54. Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E, et al. Serum interleukin-6 in schizophrenic patients. Life Sci. 1991;49:661–664
  55. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiat. 1995;19:75–83
  56. Smith RS, Maes M. The macrophage–T lymphocyte theory of schizophrenia: additional evidence. Med. Hypoth. 1995;45:135–141
  57. Spitzer RL, Williams JB, Gibbon M, First MB. Instruction Manual for the Structured Clinical Interview for DSM-IV (SCID). New York: Biometrics Research Division, New York State Psychiatric Institute; 1995;
  58. Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J. Immunol. Meth. 1992;153:115–124
  59. Villemain F, Chatenoud L, Galinowski A, Homo-Delarche F, Ginestet D, Loo H, et al. Aberrant T cell-immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry. 1989;146:609–616
  60. Waddington JL. Neurodynamics of abnormalities in cerebral metabolism and structure in schizophrenia. Schizophr. Bull. 1993;19:55–69
  61. Whicher J, Ingham E. Cytokine measurements in body fluids. Eur. Cytokine Netw. 1990;1:239–243
  62. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck DG, Anisman H, et al. Cytokine-specific central monoamine alterations induced by IL-1, -2 and -6. Brain Res. 1994;643:40–49

PII: S0920-9964(99)00171-1

Schizophrenia Research
Volume 44, Issue 3 , Pages 165-175 , 1 September 2000

Article Tools

* Image Usage & Resolution